Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Determining how to optimally use FDA-approved drugs in chronic GvHD

Iskra Pusic • 17 Feb 2023
Tandem Meetings 2023
General Belumosudil Ibrutinib Ruxolitinib

Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, emphasizes the need to conduct further studies to determine how to best use FDA-approved drugs for chronic graft-versus-host disease (GvHD), highlighting the possibility to combine several of these agents together. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Iskra Pusic

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Referral and transplant-timing decisions in AML: advice for community physicians
1:37
Referral and transplant-timing decisions in AML: advice for community physicians
Iskra Pusic • 11 Sep 2026
Early referral to specialist academic centers remains key in acute and chronic GvHD management
1:22
Early referral to specialist academic centers remains key in acute and chronic GvHD management
Iskra Pusic • 11 Sep 2026
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
1:19
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
Iskra Pusic • 11 Sep 2026

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals